The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide.

Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION ...

Dr. Shervin Naderi and his team integrate facial rejuvenation with weight loss care to manage the structural facial changes ...

While overall risk of macular degeneration remained low, a study suggests that GLP-1 drugs may have increased that risk in ...

So, what's the tea on microdosing? It's pretty much what it sounds like — taking smaller doses than the usual prescribed ...

Also: A Medicare crisis and doctors’ concerns with Kennedy’s new coronavirus vaccine policy.

The rising trend of sweet-smelling gourmand fragrances coincides with anecdotal reports from GLP-1 weight-loss drug users ...

Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...